Artiva Biotherapeutics (Nasdaq: ARTV) announced that its Board Compensation Committee approved new employee inducement grants totaling 288,800 restricted stock units for 17 new employees under the company’s 2025 Inducement Plan, effective July 14, 2026, in reliance on Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years on quarterly vesting dates of February 15, May 15, August 15 and November 15. For each employee, 25% vests on the quarterly date closest to the one-year anniversary of their start date, and the remaining units vest in 12 equal quarterly installments, subject to continued employment and applicable grant documents.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ARTV
+7.96%
10 alerts
+7.96%Session close to close
+7.0%Peak in 3 hr 56 min
$481.99MMarket Cap
0.4xRel. Volume
In the Jul 17 session, ARTV gained 7.96%, reflecting a notable positive market reaction.
Argus tracked a peak move of +7.0% during that session.
Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
The stock moved +8.0% in the session following this news. If a strong upside move followed this indu...
Analysis
The stock moved +8.0% in the session following this news. If a strong upside move followed this inducement grant news, it would contrast with prior events where updates like EULAR data still saw moves such as -7.72%. Net insider buying and moderate short positioning could amplify reactions, though the S-3 shelf’s prior use highlights ongoing financing risk.
Key Figures
Inducement RSUs granted:288,800 restricted stock unitsEmployees receiving grants:17 new employeesVesting term:4 years+5 more
8 metrics
Inducement RSUs granted288,800 restricted stock unitsAggregate grants to new employees under 2025 Inducement Plan
Employees receiving grants17 new employeesCovered by the July 14, 2026 inducement awards
Vesting term4 yearsInducement RSU vesting period
Initial vesting portion25% of grantVests on Quarterly Vesting Date closest to one-year anniversary
Subsequent vesting schedule1/12 of remaining RSUsEach of the following 12 Quarterly Vesting Dates
Quarterly Vesting DatesFebruary 15, May 15, August 15, November 15Standard vesting dates for the Inducement Grants
Pre-headline price change-8.87%Move vs prior close on 2026-07-16 before this announcement
52-week trading range$2.0701 to $14.53Low and high prior to publication
Appointment of Diego Miralles as President and Head of R&D with equity grants.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent ARTV headlines have often been followed by negative next-day moves even on seemingly positive clinical and corporate updates.
Key Terms
restricted stock units, nasdaq listing rule 5635(c)(4), inducement plan
3 terms
restricted stock unitsfinancial
"approved new employee inducement grants covering an aggregate of 288,800 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement planfinancial
"granted pursuant to Artiva’s 2025 Inducement Plan"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees.
The Inducement Grants were granted pursuant to Artiva’s 2025 Inducement Plan (the “Inducement Plan”), and were effective July 14, 2026.The Inducement Grants will vest over four years, with vesting aligned to quarterly vesting dates of February 15, May 15, August 15 and November 15 (the “Quarterly Vesting Dates”).For each new employee, 25% of the Inducement Grant will vest on the Quarterly Vesting Date closest to the one-year anniversary of the employee’s start date with Artiva, and 1/12th of the remaining restricted stock units will vest on each of the following 12 Quarterly Vesting Dates, subject to the employee’s continued employment on each applicable vesting date. The Inducement Grants are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the applicable restricted stock unit notice and agreement covering the grant.
Artiva granted the Inducement Grants as inducements material to the employees entering into employment with Artiva in accordance with Nasdaq listing Rule 5635(c)(4).
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. Artiva is developing AlloNK in combination with anti-CD20 antibodies in autoimmune disease, with the goal of delivering auto-CAR-T-like activity through a scalable, outpatient-administered treatment regimen compatible with community rheumatology settings. AlloNK is currently being evaluated across B-dell driven autoimmune diseases, including refractory rheumatoid arthritis (RA), Sjögren disease, systemic sclerosis and myositis. Initial clinical data have demonstrated encouraging activity across multiple autoimmune indications, along with a tolerability profile supportive of outpatient administration. Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
What did Artiva Biotherapeutics (ARTV) announce about new employee inducement grants on July 17, 2026?
Artiva Biotherapeutics announced approval of inducement grants covering 288,800 restricted stock units for 17 new employees. According to Artiva, these RSUs were granted under its 2025 Inducement Plan and are intended as material inducements for the employees to join the company.
How many restricted stock units are included in the new Artiva Biotherapeutics (ARTV) inducement grants?
The new Artiva inducement grants cover an aggregate of 288,800 restricted stock units. According to Artiva, these RSUs were granted to 17 new employees as employment inducements under the 2025 Inducement Plan, with vesting over a four-year period on specified quarterly dates.
What is the vesting schedule for Artiva Biotherapeutics (ARTV) July 2026 inducement RSU grants?
The inducement RSUs vest over four years on quarterly dates of February 15, May 15, August 15 and November 15. According to Artiva, 25% vests at the quarterly date closest to each employee’s one-year start anniversary, with the remainder vesting in 12 quarterly installments.
When were the new Artiva Biotherapeutics (ARTV) inducement grants effective and under which plan were they issued?
The new inducement grants were effective on July 14, 2026 under Artiva’s 2025 Inducement Plan. According to Artiva, the grants are governed by the plan’s terms and the applicable restricted stock unit notices and agreements for each participating employee.
How does Nasdaq Listing Rule 5635(c)(4) relate to Artiva Biotherapeutics’ (ARTV) July 2026 inducement grants?
Artiva granted the RSU inducement awards in reliance on Nasdaq Listing Rule 5635(c)(4), which permits equity grants as material employment inducements. According to Artiva, these grants were specifically structured as inducements for new employees entering employment with the company.
How many employees are receiving Artiva Biotherapeutics (ARTV) inducement RSUs and what are the employment conditions?
A total of 17 new employees are receiving the inducement RSUs. According to Artiva, vesting of each employee’s restricted stock units is conditioned on that employee’s continued employment through each applicable quarterly vesting date specified in the grant documents.
